Skip directly to page options Skip directly to A-Z link
Volume 16, Number 5—May 2010
Research

Effects of Pneumococcal Conjugate Vaccine 2 Years after Its Introduction, the Netherlands

Gerwin D. Rodenburg1Comments to Author , Sabine C. de Greeff1, Angelique G.C.S. Jansen, Hester E. de Melker, Leo M. Schouls, Eelko Hak, Lodewijk Spanjaard, Elisabeth A.M. Sanders2, and Arie van der Ende2
Author affiliations: Wilhelmina Children’s Hospital/University Medical Center, Utrecht, the Netherlands (G.D. Rodenburg, A.G.C.S Jansen, E. Hak, E.A.M. Sanders); National Institute for Public Health and the Environment, Bilthoven, the Netherlands (S.C. de Greeff, H.E. de Melker, L.M. Schouls); University Medical Center, Groningen, the Netherlands (E. Hak); Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam, the Netherlands (L. Spanjaard, A. van der Ende); 1, 2These pairs of authors contributed equally to this study.

Main Article

Table

Incidence rates of invasive pneumococcal diseases before and after implementation of 7-valent pneumococcal conjugate vaccine, the Netherlands*

Serotypes by patient age group, y Preimplementation period (June 2004–June 2006)
 Postimplementation period (June 2006–June 2008)
 Preimplementation vs. postimplementation
No. cases Rate No. cases Rate IRR (95% CI) p value†
Total
All ages 1,225 15.0 1,304 15.9 1.06 (0.98–1.15) 0.14
<2 68 34.5 42 22.5 0.65 (0.44–0.96) 0.006
2–4 25 8.1 26 8.7 1.07 (0.62–1.86)
5–49 206 4.1 231 4.7 1.13 (0.94–1.37)
50–64 254 16.7 292 18.5 1.11 (0.94–1.31)
>65
 672
 58.8
713
 60.2
1.02 (0.92–1.14)
Vaccine serotypes‡
All ages 570 7.0 561 6.9 0.98 (0.87–1.10)
<2 48 24.3 15 8.0 0.33 (0.19–0.59) <0.0001
2–4 17 5.5 17 5.7 1.03 (0.53–2.02)
5–49 69 1.4 70 1.4 1.02 (0.73–1.43)
50–64 114 7.5 129 8.24 1.09 (0.85–1.40)
>65
 322
 28.2
330
 27.9
0.99 (0.85–1.15)
Nonvaccine serotypes§
All ages 656 8.0 743 9.1 1.13 (1.02–1.26) 0.02
<2 20 10.1 27 14.5 1.43 (0.80–2.55)
2–4 8 2.6 9 3.0 1.16 (0.45–3.01)
5–49 137 2.8 161 3.3 1.19 (0.94–1.49)
50–64 140 9.2 163 10.3 1.12 (0.89–1.41)
>65 350 30.6 383 32.4 1.06 (0.91–1.22)

*Rate is cases/100,000 persons. IRR, incidence rate ratio; CI, confidence interval. Boldface indicates significant differences (p<0.05).
†p values shown <0.15; incidence rates pre vs. postimplementation period. Calculated by using Fisher exact test; all p values are 2 sided.
‡Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F.
§All other S. pneumoniae serotypes.

Main Article

1, 2These pairs of authors contributed equally to this study.

Page created: December 23, 2010
Page updated: December 23, 2010
Page reviewed: December 23, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external